BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...

Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...

Evercore ISI upgraded Sprouts Farmers Market (SFM) to Outperform from In Line with a price target of $120, up from $96. The ...

Notably, we dosed the first patient in a trial evaluating the combination of the TROP2 antibody-drug conjugate BNT325/DB-1305 and the PD-L1-VEGF-A bispecific BNT327/PM8002, aiming to harness the ...

The updates included data on multiple drug candidates, such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight was on BNT327, particularly after ...

BioNTech's updates included promising data from phase II and phase I/II trials for BNT327/PM8002, an anti-VEGF-A/PD-L1 bispecific. The analyst highlighted the need for BioNTech to diversify beyond its ...